S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

OptimizeRx (OPRX) Stock Forecast, Price & News

+1.68 (+6.83%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
92,403 shs
Average Volume
202,851 shs
Market Capitalization
$477.03 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OptimizeRx logo

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.


See More Headlines

Industry, Sector and Symbol

Business services, not elsewhere classified
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$61.29 million
Cash Flow
$0.13 per share
Book Value
$7.22 per share


Net Income
$380 thousand
Pretax Margin




Free Float
Market Cap
$477.03 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Computer And Technology Sector

328th out of 931 stocks

Business Services, Not Elsewhere Classified Industry

50th out of 141 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for OptimizeRx

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its earnings results on Wednesday, May, 4th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.06. OptimizeRx had a negative net margin of 4.30% and a negative trailing twelve-month return on equity of 1.76%. During the same period last year, the company posted ($0.01) earnings per share.
View OptimizeRx's earnings history

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $81.83 million.

What price target have analysts set for OPRX?

5 equities research analysts have issued twelve-month price targets for OptimizeRx's shares. Their forecasts range from $50.00 to $102.00. On average, they anticipate OptimizeRx's stock price to reach $73.50 in the next twelve months. This suggests a possible upside of 179.7% from the stock's current price.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?
OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 53, Pay $1.04M) (LinkedIn Profile)
  • Mr. Edward Stelmakh C.M.A., M.B.A., MBA, CFO & COO (Age 56, Pay $505.64k)
  • Ms. Marion K Odence-Ford, Gen. Counsel & Chief Compliance Officer (Age 57, Pay $428.12k)
  • Mr. Douglas P. Baker, Exec. VP of Fin. & Accounting (Age 65) (LinkedIn Profile)
  • Mr. Andrew Jacob D'Silva, Sr. VP of Corp. Fin.
  • Mr. Todd Inman, Chief Technology Officer (Age 67)
  • Maira Alejandra, Media Relations Mang.
  • Ms. Sheryl Kearney, HR Mang.
  • Mr. Terence J. Hamilton, Sr. VP of Pharma (Age 57)
  • Mr. Stephen L. Silvestro, Chief Commercial Officer (Age 44) (LinkedIn Profile)
What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (14.79%), Vanguard Group Inc. (6.14%), Blair William & Co. IL (4.00%), State Street Corp (3.34%), American Century Companies Inc. (3.24%) and Handelsbanken Fonder AB (3.00%). Company insiders that own OptimizeRx stock include Douglas P Baker, Douglas P Baker, Gregory D Wasson, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends for OptimizeRx

Which institutional investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including PEAK6 Investments LLC, Dimensional Fund Advisors LP, Citigroup Inc., Jacob Asset Management of New York LLC, Principal Financial Group Inc., Calamos Advisors LLC, Handelsbanken Fonder AB, and Lisanti Capital Growth LLC. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, and William J Febbo.
View insider buying and selling activity for OptimizeRx
or view top insider-selling stocks.

Which institutional investors are buying OptimizeRx stock?

OPRX stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Granite Investment Partners LLC, American Century Companies Inc., G2 Investment Partners Management LLC, Northern Trust Corp, Renaissance Technologies LLC, Premier Fund Managers Ltd, and Goldman Sachs Group Inc..
View insider buying and selling activity for OptimizeRx
or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $26.28.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $477.03 million and generates $61.29 million in revenue each year. The company earns $380 thousand in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 97 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at (248) 651-6568, via email at [email protected], or via fax at 248-453-5529.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.